Electronic Platform for Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long‐Acting Growth Hormone Therapy (LAuGH TRACK UMN)


The purpose of the study is to compare quality of life (QOL), adherence, insulin resistance, body composition and efficacy of LAGH to DGH in children with GHD.

I'm interested

up to 18 Years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Girls must be between the ages of 2 and 11 years, and boys must be between the ages of 2 and 13 years
• Have established diagnosis of pediatric growth hormone deficiency (GHD). For the purposes of the study, GHD is defined as peak growth hormone response to clonidine/arginine stimulation testing of <10 ng/mL
• Either treatment-naive or currently treated with a daily growth hormone as approved by health insurance
Exclusion Criteria:

• Any medical condition which, in the opinion of the Investigator, can be an independent cause of short stature and/or limit the response to exogenous growth factor treatment
• Current treatment with long-acting growth hormone
• Currently pregnant or breastfeeding

Drug: Long-Acting Growth Hormone (LAGH)

Growth Hormone Deficiency, Growth Hormone Treatment, Children's Health, Diabetes & Endocrine

Growth Hormone Deficiency

Brad Miller -
Brad Miller, MD, PhD
See this study on